Publications by authors named "Jihane Bouziane"
Purpose: To analyse the clinical and histological characteristics of breast cancers (BC) occurring after Hodgkin lymphoma (HL), as well as their outcome with particular attention to the effectiveness and safety of breast-conservative surgery with radiation therapy (RT).
Materials And Methods: This is a retrospective study of 218 patients who developed stage 0 to III BC after treatment for mediastinal HL between 1951 and 2022. Comprehensive demographic, clinical, and therapeutic data were collected for HL and BC, as well as survival and locoregional control.
There is new data in the fractionation modalities and these are the really the practice-changing trials of last years: can we use hypo fractionated whole breast radiotherapy in patients presented with ductal carcinoma in situ? Can we realize hypofractionated whole breast radiotherapy with simultaneous integrated boost? What about hypofractionated irradiation after mastectomy with reconstruction? Can we do hypofractionation to lymph nodes without risk of increased toxicity? The purpose of this work is to respond with the last evidence-based recently presented or published data.
View Article and Find Full Text PDFArticle Synopsis
- Recent DESTINY-Breast trials indicate that trastuzumab deruxtecan is effective for HER2-positive and HER2-low metastatic breast cancer, but the safety of combining it with radiation therapy needs further investigation.
- A retrospective study at Institut Curie Paris involved 33 patients treated with both therapies, collecting data on demographics, treatment, and toxicity profiles.
- Results showed manageable toxicity levels, with the most common being mild nausea and some instances of grade 2 toxicities; further research is necessary to confirm these findings in larger cohorts.
Article Synopsis
- The MONALEESA clinical trials found that combining ribociclib, a CDK4/6 inhibitor, with standard endocrine therapy significantly improves progression-free survival in patients with advanced or metastatic ER-positive, HER2-negative breast cancer.
- Concerns over ribociclib's toxicity during radiotherapy led most doctors to stop the medication during treatment, but initial results from two patients suggest benefits when ribociclib is continued concurrently.
- A retrospective study at Institut Curie analyzed the safety of combining ribociclib with palliative radiotherapy in metastatic breast cancer, noting positive outcomes in pain relief for the two patients who continued the medication during treatment.